A Phase II, Randomised, Open-Label, Multicentre Study of AS1402 in Combination With Letrozole as First Line Treatment in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer.

Trial Profile

A Phase II, Randomised, Open-Label, Multicentre Study of AS1402 in Combination With Letrozole as First Line Treatment in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2012

At a glance

  • Drugs BTH 1704 (Primary) ; Letrozole
  • Indications Advanced breast cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 15 Mar 2012 This trial has been recruiting in France and discontinued in Poland as reported by European Clinical Trials Database record.
    • 21 Nov 2009 Status changed from discontinued to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
    • 12 Aug 2009 Additional lead trial investigator Acton G identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top